Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis

Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing first-in-class new therapies for the treatment of blinding ocular diseases, today announced the successful outcome of a Type C meeting with the U.S. Food and Drug Administration…